ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

selatogrel

Also written as “Selatogrel”, “ACT-246475” and “Selatogrel 8 mg”.

Its studies are mostly in Myocardial Infarction · Coronary Artery Disease, led by 2 companies.

Drug pageSelatogrel: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 28, 202111 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatrisits history only101 open or runningphase 3since Jun 28, 2021Dec 20, 2017Jul 2027phase 3 · NCT04957719
Idorsia Pharmaceuticals10 open or runningphase 1since Sep 27, 2013Sep 27, 2013none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Idorsia Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2013First study: phase 1 study in Safety, Tolerability, Pharmacokinetics and PharmacodynamicsFirst studyNCT01954615 · 49 enrolled · France
  2. Jun 9, 2018Named selatogrelINNProposed as its International Nonproprietary Name in WHO's List 119 · before, ACT-246475

TargetBeta

P2RY12 →read by rule
“Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule

Other programs on P2RY12

ProgramCompanyFurthest phaseStudies
ClopidogrelruleSanofiphase 471
TicagrelorruleAstraZenecaphase 447

Studies

The one study Idorsia Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01954615Safety, Tolerability, Pharmacokinetics and Pharmacodynamics · France1CompletedMar 201249

How it is read

Names in the registry

  • “Selatogrel”, 8 entries
  • “ACT-246475”, 3 entries
  • “Selatogrel 8 mg”, 1 entry
  • “Selatogrel 16 mg”, 1 entry
  • “ACT-246475 (Group G dose to be defined)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.